CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (Nasdaq:CERS) today announced the appointment of
Timothy L. Moore to its Board of Directors. Mr. Moore, who currently
serves as executive vice president, technical operations for Kite, a
Gilead Company, brings over three decades of experience in engineering,
manufacturing, and technical operations in the biopharmaceutical
industry.
“Following an extensive search, we are delighted to welcome Tim to
Cerus’ Board of Directors,” said Daniel Swisher, Chair of the Board.
“Tim brings a wealth of manufacturing operations experience and an
impressive track record of success in helping companies in the life
sciences industry scale their global manufacturing and supply chain
operations. Tim’s extensive experience with plasma derivative and cell
therapy production lines in multiple geographies will serve Cerus well,
as we strive to establish the INTERCEPT blood system as the global
standard of care for transfused blood components.”
“I am looking forward to joining the Cerus Board and supporting the
Company’s strategic plan, including scaling the operational
infrastructure for INTERCEPT and launching their red cell product,”
commented Timothy L. Moore. “Cerus’ INTERCEPT product portfolio is set
to transform blood safety and availability across the globe, and I am
excited to work with the Company to achieve its next stage of growth.”
Prior to his current position at Kite where he has led the global
manufacturing effort for the launch of Kite’s revolutionary Yescarta
product, Mr. Moore served 12 years in various engineering, supply chain
and manufacturing leadership roles at Genentech, most recently as senior
vice president and head of global technical operations, biologics unit.
Previously in his career, Mr. Moore held senior manufacturing,
operations, and engineering positions at CSL Ltd, Armour
Pharmaceuticals, and Merck.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood transfusion safety. The INTERCEPT Blood System is designed to
reduce the risk of transfusion-transmitted infections by inactivating a
broad range of pathogens such as viruses, bacteria and parasites that
may be present in donated blood. The nucleic acid targeting mechanism of
action of the INTERCEPT treatment is designed to inactivate established
transfusion threats, such as hepatitis B and C, HIV, West Nile virus and
bacteria, as well as emerging pathogens such as chikungunya, malaria and
dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in the United States, Europe, the Commonwealth
of Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT Red Blood Cell system is in
clinical development. See http://www.cerus.com
for information about Cerus.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20180906005828/en/
Cerus Corporation
Tim Lee, 925-288-6137
Investor Relations
Director
Source: Cerus Corporation